MSB 7.69% $1.19 mesoblast limited

MSB to dispute FDA finding in Type A meeting, page-836

  1. 2,261 Posts.
    lightbulb Created with Sketch. 367
    I dont need to, the ODAC panel member who changed their vote in Aug agreed with the MSB team catagorically at the meeting that it would be unethical/impractical to recruit to an RCT for paeds GVHD. the end.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.